EYPT
Price
$6.15
Change
-$0.20 (-3.15%)
Updated
Feb 21 closing price
Capitalization
419.74M
4 days until earnings call
SLGL
Price
$0.58
Change
-$0.02 (-3.33%)
Updated
Feb 21 closing price
Capitalization
16.16M
31 days until earnings call
Ad is loading...

EYPT vs SLGL

Header iconEYPT vs SLGL Comparison
Open Charts EYPT vs SLGLBanner chart's image
EyePoint Pharmaceuticals
Price$6.15
Change-$0.20 (-3.15%)
Volume$649.36K
Capitalization419.74M
Sol-Gel Technologies
Price$0.58
Change-$0.02 (-3.33%)
Volume$22.16K
Capitalization16.16M
EYPT vs SLGL Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. SLGL commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and SLGL is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (EYPT: $6.15 vs. SLGL: $0.58)
Brand notoriety: EYPT and SLGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 73% vs. SLGL: 3%
Market capitalization -- EYPT: $419.74M vs. SLGL: $16.16M
EYPT [@Biotechnology] is valued at $419.74M. SLGL’s [@Biotechnology] market capitalization is $16.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileSLGL’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • SLGL’s FA Score: 0 green, 5 red.
According to our system of comparison, EYPT is a better buy in the long-term than SLGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 3 TA indicator(s) are bullish while SLGL’s TA Score has 2 bullish TA indicator(s).

  • EYPT’s TA Score: 3 bullish, 5 bearish.
  • SLGL’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than SLGL.

Price Growth

EYPT (@Biotechnology) experienced а -5.38% price change this week, while SLGL (@Biotechnology) price change was -4.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

EYPT is expected to report earnings on May 07, 2025.

SLGL is expected to report earnings on May 09, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($420M) has a higher market cap than SLGL($16.2M). EYPT YTD gains are higher at: -17.450 vs. SLGL (-37.641). SLGL has higher annual earnings (EBITDA): -11.32M vs. EYPT (-102.3M). EYPT has more cash in the bank: 254M vs. SLGL (28.1M). SLGL has less debt than EYPT: SLGL (1.31M) vs EYPT (21.9M). EYPT has higher revenues than SLGL: EYPT (45.7M) vs SLGL (11.7M).
EYPTSLGLEYPT / SLGL
Capitalization420M16.2M2,593%
EBITDA-102.3M-11.32M904%
Gain YTD-17.450-37.64146%
P/E RatioN/AN/A-
Revenue45.7M11.7M391%
Total Cash254M28.1M904%
Total Debt21.9M1.31M1,677%
FUNDAMENTALS RATINGS
EYPT vs SLGL: Fundamental Ratings
EYPT
SLGL
OUTLOOK RATING
1..100
7452
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
9465
P/E GROWTH RATING
1..100
1797
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLGL's Valuation (53) in the Pharmaceuticals Major industry is in the same range as EYPT (63). This means that SLGL’s stock grew similarly to EYPT’s over the last 12 months.

SLGL's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EYPT (100). This means that SLGL’s stock grew similarly to EYPT’s over the last 12 months.

SLGL's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as EYPT (98). This means that SLGL’s stock grew similarly to EYPT’s over the last 12 months.

SLGL's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as EYPT (94). This means that SLGL’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (17) in the Pharmaceuticals Major industry is significantly better than the same rating for SLGL (97). This means that EYPT’s stock grew significantly faster than SLGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTSLGL
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIHAX16.83-0.04
-0.24%
JPMorgan International Hedged Equity A
WPVLX32.97-0.50
-1.49%
Weitz Multi Cap Equity-Investor Cl
TRSCX27.67-0.51
-1.81%
Nuveen Large Cap Responsible Eq Ret
CSSCX20.91-0.53
-2.47%
Columbia Small Cap Value I C
BGGSX28.00-1.28
-4.37%
Baillie Gifford US Equity Growth I

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-3.15%
LYRA - EYPT
58%
Loosely correlated
+4.10%
ATHE - EYPT
54%
Loosely correlated
-2.63%
GLYC - EYPT
47%
Loosely correlated
-2.19%
OCUL - EYPT
46%
Loosely correlated
-3.45%
BEAM - EYPT
41%
Loosely correlated
-8.18%
More

SLGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLGL has been loosely correlated with TRAW. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SLGL jumps, then TRAW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLGL
1D Price
Change %
SLGL100%
-3.33%
TRAW - SLGL
53%
Loosely correlated
-4.48%
RAPT - SLGL
30%
Poorly correlated
-0.79%
AVXL - SLGL
29%
Poorly correlated
-3.80%
RPRX - SLGL
29%
Poorly correlated
+0.94%
EYPT - SLGL
28%
Poorly correlated
-3.15%
More